{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16792", "batch_size": 260, "batch_pos": 79, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment neutrally reports on company plans and potential response speed.", "method": "llm_batch", "batch_id": "batch_2_6268", "batch_size": 260, "batch_pos": 68, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment discusses plans for a human trial and potential response speed.", "method": "llm_batch", "batch_id": "batch_3_14884", "batch_size": 260, "batch_pos": 50, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment reports factual information about trial plans and response speed, without posing a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_15756", "batch_size": 260, "batch_pos": 48, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The phrase 'respond very quickly' describes capability, not explicit calming about current safety.", "method": "llm_batch", "batch_id": "batch_5_11380", "batch_size": 260, "batch_pos": 46, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment uses 'small human trial' but this is not the specific 'minimiser + scale contrast' pattern defined.", "method": "llm_batch", "batch_id": "batch_6_13968", "batch_size": 260, "batch_pos": 30, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment discusses plans for a human trial and potential response speed but contains no bare negation.", "method": "llm_batch", "batch_id": "batch_7_11736", "batch_size": 260, "batch_pos": 27, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes planned future action and potential future capability ('company plans to launch a small human trial', 'could respond very quickly in an outbreak scenario').", "method": "llm_batch", "batch_id": "batch_8_9576", "batch_size": 260, "batch_pos": 249, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
